High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active antiretroviral therapy

Clinical Infectious Diseases

Volumn 52, Issue 3, 2011, Pages 378-386

  Mondy, Kristin E ^a,b   Gottdiener, John ^c   Overton, E Turner ^a   Henry, Keith ^d   Bush, Tim ^e   Conley, Lois ^e   Hammer, John ^f   Carpenter, Charles C ^g   Kojic, Erna ^g   Patel, Pragna ^e   Brooks, John T ^e  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d HENNEPIN COUNTY MEDICAL CENTER   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f Denver Infectious Disease Consultants   (United States)

^g MIRIAM HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; C REACTIVE PROTEIN; CANNABIS; RITONAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY; FEMALE; HEART ATRIUM ENLARGEMENT; HEART LEFT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RACE; SMOKING; SYSTOLIC DYSFUNCTION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; ECHOCARDIOGRAPHY; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 79951825588     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciq066     Document Type: Article

References (53)

1. Hammer SM, Eron JJ, Reiss P, et al. Antiretroviral treatment of adult HIV infection. 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008;300:555-570.
2. The DAD. Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-1735.
3. Holmberg SD, Tong TC, Ward DJ, et al. Protease inhibitor drug use and adverse cardiovascular outcomes in ambulatory HIV-infected persons. Lancet 2002;360:1747-1748.
4. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005;352:48-62. (Pubitemid 40075680)
5. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-22896.
6. Meng Q, Lima JA, Lai H, et al. Use of HIV protease inhibitors is associated with left ventricular morphologic changes and diastolic dysfunction. J Acquir Immune Defic Syndr 2002;30:306-310. (Pubitemid 34774078)
7. th conference on retroviruses and opportunistic infections, February 2008, Boston, Massachusetts.
8. Barbaro G, Lorenzo GD, Grisorio B, et al. Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients. N Engl J Med 1998;339:1093-1099. (Pubitemid 28465756)
9. Martinez-Garcia T, Sobrino JM, Pujol E, et al. Ventricular mass and diastolic function in patients infected by the human immunodeficiency virus. Heart 2000;84:620-624.
10. Fisher SD, Easley KA, Orav EJ, et al. Mild dilated cardiomyopathy increased left ventricular mass predict mortality: the prospective P2C2 HIV Multicenter Study. Am Heart J 2005;150:439-447. (Pubitemid 41317610)
11. Tanum J, Ishizaki A, Gatanaga H, et al. Dilated cardiomyopathy in an adult human immunodeficiency virus type 1-positive patient treated with a zidovudine-containing antiretroviral regimen. Clin Infect Dis 2003;37: e109-e111.
12. Domanski MJ, Sloas MM, Follmann DA, et al. Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus. J Pediatr 1995;127:137-146.
13. Frerichs FC, Dingemans KP, Brinkman K. Cardiomyopathy with mitochondrial damage associated with nucleoside reverse-transcriptase inhibitors. N Engl J Med 2002;347:1895-1896. (Pubitemid 35417789)
14. Yan Q, Jay P, Hruz PW. Acute effects of HIV protease inhibitors on the failing heart. Antivir Ther 2006;11: L11.
15. Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV seronegative men. AIDS 2001;15:11-18.
16. Miller KD, Jones E, Yanovski JA, et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998;351:871-875. (Pubitemid 28121176)
17. Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008;177:108-113.
18. Opravil M, Pechère M, Speich R, et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV cohort study. Am J Respir Crit Care Med 1997;155:990-995. (Pubitemid 27133414)
19. Zuber JP, Calmy A, Evison JM, et al. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis 2004;38:1178-1185. (Pubitemid 38951268)
20. Hsue P, Waters D, Farah H, et al. HIV is associated with pulmonary hypertension independent of known risk factors. Circulation 2005;112:97.
21. Pugliese A, Isnardi D, Saini A. Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J Infect 2000;40:282-284. (Pubitemid 30447185)
22. Vellozzi C, Brooks JT, Bush TJ, et al. The study to understand the natural history of HIV and AIDS in the era of effective therapy (SUN Study). Am J Epidemiol 2009;169:642-652.
23. Gribble JN, Miller HG, Rogers SM, Turner CF. Interview mode and measurement of sexual behaviors: methodologic issues. J Sex Res 1999;36:16-24. (Pubitemid 29118091)
24. Bachmann LH, Grimley DM, Chen H, et al. Risk behaviours in HIV-positive men who have sex with men participating in an intervention in a primary care setting. nt J STD AIDS 2009;20:607-612.
25. Gottdiener JS, Bednarz J, Devereux RD, et al. American Society of Echocardiography: recommendations for use of echocardiography in clinical trials. A report from the American Society of Echocardiography's nomenclature and standards committee and the task force on echocardiography in clinical trials. J Am Soc Echocardiogr 2004;17:1086-1019.
26. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification. A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group. J Am Soc Echocardiogr 2004;18:1440-1460.
27. Brucks S, Little WC, Caho T, et al. Contribution of left ventricular diastolic dysfunction to heart failure regardless of ejection fraction. Am J Cardiol 2005;95:605-606.
28. Munagala VK, Jacobsen SJ, Mahoney DW, Rodeheffer R, Bailey KR, Redfield MM. Association of newer diastolic function parameters with age in health subjects: a population based study. J Am Soc Echocardiogr 2003;16:1051-1056.
29. de Simone G, Daniels SR, Devereux RB, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol 1992;20:1251-1260.
30. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997;336:111-117. (Pubitemid 27020889)
31. Redfield MM, Jacobsen SJ, Burnett JC, Mahoney DW, Bailey KR, Rodeheffer RJ. Asymptomatic diastolic dysfunction: appreciating the scope of the heart failure epidemic. JAMA 2003;289:194-202. (Pubitemid 36068707)
32. Davies M, Hobbs F, Davis R, et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet 2001;358:439-444. (Pubitemid 32769849)
33. Abhayaratna WP, Seward JB, Appleton CP, et al. Left atrial size: physiologic determinants and clinical applications. J Am Coll Cardiol 2006;47:2357-2363. (Pubitemid 43866385)
34. Tsang SM, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. J Am Coll Cardiol 2002;90:1284-1289. (Pubitemid 35449471)
35. Stritzke J, Markus MP, Duderstadt S, et al. The aging process of the heart: obesity is the main risk factor for left atrial enlargement during aging. The MONICA/KORA (Monitoring of Trends and Determinations in Cardiovascular Disease/Cooperative Research in the Region of Augsburg) study. J Am Coll Cardiol 2009;54:1982-1989.
36. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-1397. (Pubitemid 38419992)
37. Zebrack JS, Anderson JL, Maycock CA, et al. Usefulness of highsensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol 2002;89:145-149. (Pubitemid 34132900)
38. Henry K, Kitch D, Dube M, et al. C-reactive protein levels over time and cardiovascular risk in HIV-infected individual suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s. AIDS 2004;18:2434-2437. (Pubitemid 40065914)
39. Lau B, Sharrett AR, Kingsley LA, et al. C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med 2006;166:64-70. (Pubitemid 43063843)
40. Triant VA, Meigs J. Grinspoon, S. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 2009;51:268-273.
41. Hadigan C, Meigs JB, Rabe J, et al. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2001;86:939-943. (Pubitemid 32207521)
42. Torriani FJ, Komarow L, Parker RA. Endothelial function in human immunodeficiency virus-infected antiretroviral-Naive subjects before and after starting Potent antiretroviral therapy. J Am Coll Cardiol 2008;52:569-576.
43. Strategies for Management of Anti-Retroviral Therapy/INSIGHT; D:A:D Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008;22: F17-F24.
44. Hsue PY, Squires K, Bolger AF. Screening and assessment of coronary heart disease in HIV-infected patients. Circulation 2008;118: e41-e347.
45. Sabin CA, Worm SW, Weber R, et al. D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008;371:1417-1426.
46. Wang X, Chai H, Lin PH, Yao Q, Chen C. Roles and mechanisms of human immunodeficiency virus protease inhibitor ritonavir and other anti-human immunodeficiency virus drugs in endothelial dysfunction of porcine pulmonary arteries and human pulmonary artery endothelial cells. Am J Pathol 2009;174:771-781.
47. Mondy K, Tebas P. Emerging problems of bone in HIV disease. Clin Infect Dis 2003;36: S101-S1105.
48. Overton ET, Mondy K, Bush TJ, et al. Factors associated with low bone mineral density (BMD) in a cohort of HIV-infected U. S. adults-baseline results from the SUN study [abstract 836]. In: Program and abstracts of the 13th Conference on Retroviruses Opportunistic Infections, Los Angeles, CA, February 2007.
49. Overton E, Nurutdinova D, Freeman J, Seyfried W, Mondy K. Factors associated with renal dysfunction within an urban HIV cohort in the era of HAART. HIV Med 2009;10:343-50.
50. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003;33:506-512. (Pubitemid 36886080)
51. McQuillan BM, Picard MH, Leavitt M, Weyman AE. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation 2001;104:2797-2802. (Pubitemid 33126653)
52. Kircher BJ, Himelman RB, Schiller NB. Noninvasive estimation of right atrial pressure from the inspiratory collapse of the inferior vena cava. Am J Cardiol 1990;66:493-496. (Pubitemid 20259386)
53. Kitahata MM, Gange SJ, Abraham AA, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009;360:1815-1826.